GlassScriptAzurion 7 B12
Payments companies reported to CMS as associated with Azurion 7 B12. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Azurion 7 B12, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Azurion 7 B12
These are the largest totals companies reported as associated with Azurion 7 B12. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Jasvindar Singh | Saint Louis, MO | Interventional Cardiology | $6,699.91 |
| Dharam Kumbhani | Dallas, TX | Interventional Cardiology | $46.75 |
Share this page
The CSV has this whole record: yearly totals, every maker, the specialty mix, and the clinicians with the largest associated totals.
Prescribed Azurion 7 B12?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.